Gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome has been reported to occur either in unilateral adrenal adenoma or in bilateral macronodular adrenal hyperplasia. A 33-yr-old woman with Cushing's syndrome was found to have two 2.5-to 3-cm nodules in the right adrenal on computed tomography scan; the left adrenal appeared normal except for the presence of a small 0.8 ϫ 0.6-cm nodule. Uptake of iodocholesterol was limited to the right adrenal. Plasma morning cortisol was 279 nmol/L fasting and 991 nmol/L postprandially, and ACTH remained suppressed. Plasma cortisol increased after oral glucose (202%) or a lipid-rich meal (183%), but not after a protein-rich meal (95%) or iv glucose (93%); the response to oral glucose was blunted by pretreatment with 100 g octreotide, sc. Plasma cortisol and GIP levels were positively correlated (r ϭ 0.95; P ϭ 0.0001); cortisol was stimulated by the administration of human GIP iv (225%), but not by GLP-1, insulin, TRH, GnRH, glucagon, arginine vasopressin, upright posture, or cisapride orally. A right adrenalectomy was performed; GIP receptor messenger ribonucleic acid was overexpressed in both adrenal nodules and in the adjacent cortex. Histopathology revealed diffuse macronodular adrenal hyperplasia without internodular atrophy. Three months after surgery, fasting plasma ACTH and cortisol were suppressed, but cortisol increased 3.6-fold after oral glucose, whereas ACTH remained suppressed; this was inhibited by octreotide pretreatment, suggesting that cortisol secretion by the left adrenal is also GIP dependent. We conclude that GIP-dependent nodular hyperplasia can progress in an asynchronous manner and that GIPR overexpression is an early event in this syndrome. (J Clin Endocrinol Metab 84: 2616 -2622, 1999 
F OOD-DEPENDENT adrenal Cushing's syndrome has been reported in recent years in patients with either bilateral macronodular adrenal hyperplasia (1-3) or single unilateral adrenal adenoma (3) (4) (5) (6) (7) ; other cases of Cushing's syndrome and periodic hormonogenesis of unknown cause were also probably secondary to the same etiology (8) . Abnormal adrenal regulation of cortisol production by gastric inhibitory polypeptide (GIP; also known as glucose-dependent insulinotropic polypeptide) in vivo (1, 2, 5) or in vitro (1, 3, (5) (6) (7) suggested that this new etiology of Cushing's syndrome may be secondary to either an ectopic expression or an activating mutation of GIP receptors (GIPR) not normally expressed or functional in adrenal cortical tissues. The human GIPR complementary DNA (cDNA) and gene have now been cloned (9, 10) ; the gene is composed of 14 exons spanning approximately 13.8 kb of DNA and is localized on chromosome 19q13.3 (9) . Recent studies indicate that GIPdependent Cushing's syndrome results from the adrenal overexpression of the GIPR in the adrenal adenoma or hyperplasia tissues compared to that in normal adult (3, 6, 7, 11) or fetal adrenal cortex (3, 11) or that in non-GIP-dependent adrenal Cushing's syndrome tissues (3, 5, 6, 11) ; no mutation of the GIPR cDNA was identified in the affected adrenal tissues (6, 11) . The small amount of GIPR messenger ribonucleic acid (mRNA) detected in normal adrenal tissues after at least 35 cycles of amplification was not efficiently coupled to steroidogenesis (1, 3, 6, 11) , such that the concept of functional ectopic receptor remains valid.
The molecular mechanisms regulating tissue-specific expression of GIPR are still unknown, as are those leading to its increased adrenal expression. An acquired somatic mutation inducing the overexpression of GIPR may be responsible for the clonal expansion resulting in a single GIPdependent cortisol-secreting adenoma; in the case of GIP-dependent bilateral macronodular adrenal hyperplasia, where all adrenal cells exhibit hyperplasia, the mutation must have occurred before the early stages of adrenal cortex embryogenesis. It is unclear, however, whether the ectopic expression of the GIPR precedes and is responsible for the adrenal overgrowth in addition to the regulation of cortisol secretion or whether the GIPR overexpression is secondary to dedifferentiation during a proliferative process caused by another pathophysiology. We now report a patient with GIPdependent Cushing's syndrome with asynchronous development of bilateral nodular hyperplasia in whom there is evidence that the adrenal overexpression of the GIPR was present at the stage of hyperplasia as well as in larger nodules.
Case Report
A 33-yr-old woman was referred for evaluation of Cushing's syndrome, which had become symptomatic during the last 2-3 yr. She had experienced an 8-kg weight gain, headaches, high blood pressure up to 170/112 mm Hg, fatigue, sleep disturbances, lack of concentration, and emotional lability; she became amenorrheic during the last 4 months and noted muscle cramps and decreased muscle strength. There were no particular symptoms related to food intake and no gastrointestinal disturbances. There was no family history of endocrine diseases. Her oral daily medication included 4 mg perindopril (Coversyl, Servier Canada, Inc., Laval, Qc, Canada), 25 mg hydrochlorothiazide, 80 mg propranolol (Inderal, Wyeth-Ayerst, Labroatories, Inc., Saint-Laurent Qc, Canada) for control of high blood pressure, and 100 mg fluvoxamine (Luvox, Solvay Pharma, Inc., Scarborough, Ont, Canada) with 50 mg trazodone (Desyrel, Bristol-Myers Squibb Canada, Inc., Montreal, Qc, Canada) for symptoms of depression. On physical examination, height was 1.57 m, weight was 56.2 kg, and body mass index was 22.8. Blood pressure was 168/104 mm Hg, and heart rate was regular at 80 beats/min. There was central obesity, with rounded face and mild supraclavicular fat pads, but no abdominal striae. There was a mild facial down and normal skin pigmentation, but otherwise normal physical examination, including muscle strength.
Initial investigation had included elevated free urinary cortisol level of 1077 nmol/day (normal range, 90 -330 nmol/day); morning fasting plasma cortisol was 279 nmol/L. Morning plasma ACTH was decreased at 0.3 pmol/L (normal range, 2-12 pmol/L). Serum levels were: dehydroepiandrosterone sulfate (DHEAS), 1.5 mol/L (normal range, 0.9 -11.6); testosterone, 0.4 nmol/L (normal range, Ͻ2.9); FSH, 3.6 U/L; LH, 0.4 U/L; and PRL, 10 g/L. Blood electrolytes and fasting and postprandial glucose were normal, whereas low density lipoprotein cholesterol and triglycerides were elevated at 5.78 and 2.99 mmol/L, respectively. An abdominal computed tomography scan revealed that the right adrenal was the site of two 2.5-to 3-cm nodules; the left adrenal was of normal morphology, except for the presence of a 0.8 ϫ 0.6-cm posterosuperior nodule. An iodocholesterol scan performed without dexamethasone suppression showed uptake of the tracer only in the right adrenal.
Materials and Methods

Clinical studies
The study protocols were approved by the institutional review committee, and written informed consent was obtained from the patient. Medications were discontinued for at least 1 week before conducting the evaluation. Studies were performed after an overnight fast in the supine position for 60 min before testing. An iv dexamethasone suppression test (1 mg/h from 1100 -1500 h) was performed as described previously (1), where the patient remains fasting until the end of the infusion of dexamethasone. The protocol to screen for potential adrenal ectopic receptors included serial measurements at 30-to 60-min intervals during 2-3 h of plasma ACTH, cortisol, aldosterone, 17-hydroxyprogesterone, free testosterone, DHEAS, and estradiol during the course of the various tests, which were performed sequentially over the course of several days. Tests included the administration of 100 g GnRH, iv (Factrel, WyethAyerst Laboratories, Inc., Saint-Laurent, Canada); 200 g TRH, iv (Relefact, Hoechst-Roussel, Montreal, Canada); 10 IU arginine vasopressin, im (Pitressin, Parke-Davis, Scarborough, Canada); 1 mg glucagon, iv (Eli Lily Canada, Inc., Scarborough, Canada); 0.2 U/kg regular human insulin, iv (Humulin, Eli Lily Canada, Inc.); 10 mg cisapride, orally (Prepulsid, Janssen Pharmaceuticals, Mississauga, Canada); and 250 g ACTH-(1-24), iv (Cortrosyn, Organon Canada, Scarborough, Canada). Other tests included a standard mixed meal and a posture test performed by a 2-h supine position, followed by a 2-h ambulation period.
To study the effects of carbohydrates, proteins, or lipids on cortisol secretion, the patient sequentially received orally at 3-h intervals 75 g oral glucose, an isocaloric protein-rich meal, or a lipid-rich meal as described previously (1) . On a different day, 25 g glucose were administered iv, and 3 h later, 100 g octreotide (Sandostatin, Novartis, Pointe Claire, Canada) were administered sc 60 min before repeating an oral 75-g glucose challenge; plasma levels of cortisol, ACTH, GIP, and insulin were determined at regular intervals during these tests. Human GIP (Bachem, Torrance, CA) was prepared and infused at a rate of 0.6 g/kg⅐min during the administration of 150 cc/h 10% glucose as described previously (1) ; to maximize the response, endogenous levels of GIP were suppressed by the sc administration of 100 g octreotide 90 min before starting the infusion of human (h) GIP. Glucagon-like peptide-1 (GLP-1; Bachem) was provided by Dr. John Dupre (London, Canada) as 50 g/mL in 0.1% human serum albumin and was infused at a rate of 0.75 pmol/kg⅐min also under 10% glucose, as described previously (12); the GLP-1 infusion was not preceded by the administration of octreotide.
Assays
Plasma and urinary cortisol and plasma estradiol were measured by immunofluorometric assay (Bayer Immuno I System, Tarytown, NY), ACTH by immunoradiometric assay (Allegro, Nichols Institute Diagnostics , San Juan Capistrano, CA), and plasma GIP (Peninsula Laboratories, Inc. Belmont, CA) and other steroid hormones by commercial RIA kits.
RNA preparation and GIPR RT-PCR
Total RNA was extracted from adrenals by the guanidium-phenol chloroform method (13) . First strand cDNA synthesis was carried out with 2 g total RNA and random primers (hexamers) by using Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc., Burlington, Canada) as recommended by the manufacturer. In control reactions, reverse transcriptase was omitted to ensure that the PCR amplification did not result from contaminating genomic DNA. The PCR reaction contained 10 mmol/L Tris-HCl (pH 8.3), 1.5 mmol/L MgCl 2 , 50 mmol/L KCl, 0.2 mmol/L of each deoxy-NTP, 10 pmol each of sense and antisense primers specific for the human GIP receptor (GenBank U39231), one fifth of the RT reaction, 2.5 U Taq DNA polymerase, and 5% formamide. The amplification was achieved with 35 cycles (94 C, 30 s; 49 C, 30 s; 72 C, 30 s) with a pair of primers specific for hGIPR [5Ј-TGCTAGCCCTGCTCATCTTGA-3Ј (513-533) and 5Ј-ACACGGG-GATCCCGCCCCCTA-3Ј (1453-1474)]. The PCR products were separated on agarose gel. The RNA samples were also amplified (94 C, 30 s; 51 C, 30 s; 72 C, 30 s) with a pair of primers specific for the human ␤-actin cDNA (5Ј-GATTCCTATGTGGGCGA-3Ј and 5Ј-GATTCCTATGT-GGGCGA-3Ј).
Results
During an initial screening, morning fasting plasma cortisol increased from 279 to 455 nmol/L before and to 991 nmol/L 2 h after the noontime meal; plasma ACTH remained less than 0.4 pmol/L. An iv dexamethasone suppression test failed to decrease plasma cortisol levels and did not prevent postprandial elevations of cortisol (276%). A standard mixed meal was able to reproduce the increase in plasma cortisol from 376 to a peak value of 888 nmol/L at 90 min (Table 1) ; the iv administration of ACTH-(1-24) also resulted in a stimulation of plasma cortisol (180%), whereas the upright posture test, TRH, GnRH, glucagon, insulin-induced hypoglycemia, arginine vasopressin, and cisapride were without effect (Table 1) . Plasma cortisol increased in response to 75 g oral glucose (202%) and a lipid-rich meal (183%), but not after a protein-rich meal (95%) or 25 g glucose, iv (93%); the response to oral glucose was decreased by pretreatment with 100 g octreotide, sc (Fig. 1 ). Plasma cortisol elevations followed and were positively correlated with plasma GIP levels during these various tests (r ϭ 0.95; P ϭ 0.0001). Cortisol levels were stimulated by the infusion of 0.6 g/kg⅐h hGIP (225%), but not by 0.75 pmol/kg⅐min GLP-1 (88%) (Fig. 2) ; plasma insulin levels increased from 138 to a peak value of 344 pmol/L after 60 min of GLP-1 infusion. The plasma levels of GIP reached during the hGIP infusion (1000 ng/L) were similar to those produced by the 75-g oral glucose test (1202 ng/L). The infusion of GIP in vivo induced an increase in plasma levels of 17-hydroxyprogesterone and free testosterone, but not of aldosterone, DHEAS, or estradiol (Table 2) ; plasma aldosterone increased after upright posture (46 to 234 pmol/L) or cisapride administration (53 to 524 pmol/L).
The right adrenal was removed by laparoscopy and was found to include two yellow-tan-colored macronodules, whereas the adjacent cortex appeared macroscopically normal (Fig. 3) . However at histology, diffuse hyperplasia was present in the adrenal cortex, forming small micronodules outside of the two macronodules, which were composed of an alternance of clear and acidophilic cells (Fig. 3) . The levels of GIPR mRNA in the adrenal and control tissues were detected using RT-PCR amplification and ethidium bromide staining. The expected size (980 bp) GIPR band was detected and overexpressed in both of this patient's right adrenal nodules (Fig. 4, lanes 2 and 3) , whereas it was absent in the control normal adult adrenal cortex (lane 5). Interestingly, a GIPR band was also detectable in the patient's hyperplastic adrenal cortex adjacent to the macronodules (lane 4). The GIPR bands in this patient's macronodules were similar to those found in the previously reported positive control (5, 11) with a documented GIP-dependent adrenal adenoma (lane 1) or in normal pancreas (lane 7).
Suppression of the hypothalamic-pituitary-adrenal axis was present postoperatively, and oral replacement with hydrocortisone was adjusted progressively to 20 mg in the morning and 10 mg in the afternoon. Three months after surgery, fasting morning plasma ACTH and cortisol were still suppressed, but plasma cortisol increased reproducibly 
a Tests were performed 2 h after a mixed meal.
FIG. 1. Plasma cortisol and GIP responses to the oral administration of 75 g glucose (F), a protein-rich meal (f), or a lipid-rich meal (OE); iv administration of 25 g glucose (E); and oral administration of 75 g glucose 1 h after the sc injection of 100 g octreotide (Ⅺ) in the patient with food-dependent cortisol production. The first three tests were performed consecutively at 3-h intervals on the same day; the last two tests were also conducted sequentially at 3-h interval on the following day.
FIG. 2. Plasma cortisol concentrations during iv infusion of 10% glu-
cose at 150 cc/h with the additional infusion of either GIP at a rate of 0.6 g/kg⅐h (F) or GLP-1 at a rate of 0.75 pmol/kg⅐min (OE) during 120 min in the patient with food-dependent cortisol production. The GIP infusion was preceded 90 min earlier by the sc injection of 100 g octreotide to suppress endogenous levels of GIP.
(362%) after 75 g glucose, orally. ACTH remained suppressed, but plasma GIP increased normally (Fig. 5) . The response of plasma cortisol to 75 g oral glucose was abolished when the GIP stimulation was inhibited by pretreatment with 100 g octreotide, sc. One year after the surgery, the patient still required replacement with 20 mg hydrocortisone daily because of the persistent suppression of the hypothalamic-pituitary-adrenal axis; 24-h urinary free cortisol levels are maintained in the normal range on this medication. Signs and symptoms of Cushing's syndrome have disappeared, weight has decreased to 50.8 kg, and the patient is normotensive without any other medication. On repeat abdominal computed tomography scan, the left adrenal nodule now measures 0.8 ϫ 0.9 cm. A 75-g oral glucose test was performed in the mother and two sisters of this patient; in each case, plasma levels of cortisol decreased, as expected, with the diurnal rhythm and were not stimulated by the increase in plasma levels of GIP (Fig. 5 ).
Discussion
Our investigation clearly indicated that this patient presented primary ACTH-independent Cushing's syndrome. Since the initial descriptions of GIP-dependent Cushing's syndrome (1, 2), we suggested that primary adrenal Cushing's syndrome could result from the ectopic or abnormal adrenal expression of a wide diversity of hormone receptors; this hypothesis is tested using a protocol that produces transient fluctuations of various hormones, which could be the ligands for potential ectopic adrenal receptors and thus induce ACTH-independent cortisol production. This protocol was recently successful in identifying abnormal responses to vasopressin (14) and ectopic ␤-adrenergic receptors (15) in patients with bilateral macronodular adrenal hyperplasia. The initial investigation of this patient clearly suggested the possibility of periodic hormonogenesis, as plasma cortisol levels showed erratic diurnal variations. The food dependence was suggested by an increase in cortisol 2 h postpran- dially, and this was confirmed by the tests with mixed meals with or without dexamethasone suppression. The pattern of cortisol response to various oral test meals, the absence of stimulation after iv glucose, and the inhibition of oral glucose response by octreotide all supported the idea that the mediator was a gastrointestinal hormone. The good correlation between plasma GIP and cortisol levels supported the idea that GIP could be the mediator; however, GLP-1, another important incretin that responds to the same secretagogues, could have been another candidate. The cortisol response to the infusion of physiological concentrations of GIP and the absence of response to GLP-1 clearly indicated that this patient had GIP-dependent adrenal Cushing's syndrome. The lack of response of GIP and cortisol to the protein-rich meal, a relatively weaker secretagogue of GIP, was probably secondary to the fact that the GIP levels had not completely returned to baseline after the more potent effects of the oral glucose test. GIP-dependent Cushing's syndrome has been reported in a relatively small number of patients to date (1-7) ; however, this patient presented several features that render the case of particular interest. Previous patients with GIP-dependent Cushing's syndrome had fasting plasma cortisol levels ranging from as low as 4 -47 nmol/L (5), 68 -140 nmol/L (7), 102-119 nmol/L (2), 121-200 nmol/L (6), and 146 nmol/L (5) to 160 -193 nmol/L (1); the current patient had fasting plasma cortisol ranging between 279 -480 nmol/L, which indicates that GIP-dependent Cushing's syndrome should not be excluded without performing a test meal. It has been previously proposed that the suppression of ACTH coupled with the low levels of GIP in the fasting state were responsible for the decreased plasma cortisol levels, which can be accompanied by symptoms of relative cortisol insufficiency (1, 2) . The various other tests performed were not able to identify another abnormal receptor that could have explained the relatively normal fasting levels of cortisol in this patient. We cannot rule out the existence of ectopic receptors for other hormones that our protocol would not have identified; alternatively, a proportion of cortisol production by the two large nodules may be autonomous and non-GIP dependent.
Food-or GIP-dependent Cushing's syndrome was previously identified in patients with either bilateral large macronodular adrenal hyperplasia (1-3) or single unilateral adrenal adenoma (3-7). We were initially unclear whether this patient had two distinct adenomas in the right adrenal and a nonfunctional incidentaloma in the left adrenal, as the iodocholesterol uptake was restricted to the right adrenal. The macroscopic appearance of the right adrenal tended to support the first hypothesis; however, the histological findings clearly indicate the presence of macronodular adrenal hyperplasia. There was one preliminary report of the coexistence of a schwannoma, pigmented skin lesions in a patient with GIP-dependent bilateral nodular hyperplasia that contained lipofuscin (3); there were no similar characteristics reminiscent of the Carney complex (16) in our or other patients.
This study confirmed the increased expression of GIPR mRNA in the two GIP-dependent macronodules, as reported previously in patients with large bilateral adrenal hyperplasia or unilateral adenomas and GIP-dependent Cushing's syndrome (3, (5) (6) (7) 11) ; however, GIPR overexpression was also detectable in this patient's adrenal cortex adjacent to the two larger nodules at a stage of relatively early hyperplasia. This finding supports the possibility that this patient has bilateral disease; the probable increased expression of GIPR in the small left adrenal cortex and nodule would explain the GIP-dependent cortisol production that was still present after right adrenalectomy. The previous sequencing of the GIPR cDNA indicated the existence of spliced isoforms lacking exons 4 and 9 in the GIP-dependent or normal adrenal tissues and the absence of receptor mutation in GIP-dependent adrenals (6, 11) ; the presence of an isoform lacking exon 9 is not detectable on the gel in Fig. 5 because the 61-bp difference is not resolved, and the two bands appear as a single 980-bp band.
The molecular mechanisms regulating tissue-specific expression of GIPR are still unknown, as are those leading to its increased adrenal expression. The cloning and characterization of the 5Ј-promoter and 3Ј-regulatory regions of the GIPR gene and of their specific transcription factors will be necessary to elucidate this question. It is unclear whether the ectopic expression of the GIPR precedes and is responsible for the adrenal overgrowth in addition to the regulation of cortisol secretion or whether the GIPR expression is a secondary phenomenon occurring during the course of the adrenal proliferation resulting from another primary pathophysiology. The presence of abnormal GIPR expression at the stage of early hyperplasia found in this patient argues in favor of a primary role and suggests that its overexpression precedes the nodular formation and may thus be at least partly responsible for the proliferative process. Chabre et al. secretory pattern suggests that in this case, the cells overexpressing the GIPR have a fasciculata phenotype, with a predominance of cortisol production without a significant stimulation of aldosterone or DHEAS production; different patterns were found previously in vasopressin-or catecholamine-dependent Cushing's syndrome (14, 15) .
The concept of alterations in G protein coupled-receptors and/or postreceptor events leading to increased cAMP and proliferation is now well established (17) and was well studied in somatotroph and thyroid cells (18 -20) . Our hypothesis is that ectopic or abnormal expression of a hormone receptor capable of being coupled to adenylyl cyclase places the adrenal cells under the stimulation of a trophic factor that is not under a regulatory negative feedback by glucocorticoids; this constitutes an unregulated new trophic stimulus that leads to increased function and possibly to a proliferative advantage. A recent study indicates that the hormone-stimulated LH receptor can act as an adrenocortical tumor promoter when ectopically expressed in the adrenal cortex of mice transgenic for the inhibin ␣-subunit promoter/simian virus 40 T antigen fusion gene (21) . It remains to be shown whether the adrenocortical expression of an ectopic receptor without another oncogenic event would be sufficient to induce adrenal overgrowth. The asynchronous nature of nodule formation observed in this patient suggests that the initial mutation is not uniformly distributed in all adrenocortical cells, or that other secondary events are necessary to generate within the hyperplastic cell population a clonal proliferation of selected cells. Bilateral macronodular adrenal hyperplasia is usually sporadic, but rare familial cases have been reported (22, 23); we have not found any evidence of GIP-dependent stimulation of cortisol production in three siblings of this patient.
The characterization of the pathophysiology of adrenal hyperplasias or tumors can eventually lead to diverse pharmacological therapies as alternatives to adrenalectomy. This has now been illustrated by the short term improvement of hypercortisolism with octreotide in GIP-dependent Cushing's syndrome (2, 5) and by the long term control of ectopic ␤-adrenergic receptors by propranolol (15) . It would be ben- FIG. 5 . Plasma cortisol and GIP responses to 75 g oral glucose administration given 3 months after right adrenalectomy in the patient with GIP-dependent Cushing's syndrome (left panel) and in her mother and two sisters (right panel). After the right adrenalectomy (left panel), tests were performed on two different mornings, after a 12-h overnight fast either without (F), or 60 min after the sc administration of 100 g octreotide (OE); oral replacement with hydrocortisone was omitted until the end of the test. The oral administration of 75 g glucose was also performed in the mother (ࡗ) and in two sisters (E and Ⅺ) in the morning after a 12-h overnight fast without octreotide (right panel). eficial for this and other patients with GIP-dependent Cushing's syndrome to have access to an effective antagonist of the GIPR such as GIP-(7-30)-NH 2 (24) to correct the hypercortisolism and possibly prevent the progression of adrenal cell proliferation.
